



*Kevin Hall*

Executive Director  
Chronic Pain Toronto  
[chronicpaintoronto@gmail.com](mailto:chronicpaintoronto@gmail.com)  
[www.chronicpaintoronto.com](http://www.chronicpaintoronto.com)

## **Attention: Canadian Medical Cannabis Industry Association (CMCIA)**

3400 One First Canadian Place  
P.O. Box 130  
Toronto, Ontario  
M5X 1A4

**Chronic Pain Toronto is inviting all Canadian Licensed Producers to participate in a research study on how to choose a licensed producer. Members of the CMCIA will receive a 25% discount to participate.**

## **Research Survey: How to choose a licensed producer?**

Chronic Pain Toronto, a patient advocacy group out of Toronto, Ontario, is generating a research survey to assist the medical cannabis industry, physicians, patients and the government in determining what makes a quality Licensed Producer (LP) as well as identifying areas requiring improvement.

### **Background**

Medical Cannabis is being more commonly used to treat a variety of symptoms and diseases around the world. Patients and physicians have no way to evaluate what makes a good supplier/producer of medical cannabis.

The number one and two questions Chronic Pain Toronto gets when it comes to medical cannabis are, "how do you know what Licensed Producer to use and what medical cannabis strains are good for my condition(s)?"

As strains will vary depending on a patient's symptoms, age, genetics, and disease this study will only focus on "how do you know what LP to use and how do they rank amongst their peers?"

Data will be gathered through patient surveys based upon the follow criteria:

- Quality
- Consistency
- Customer Service
- Pricing
- Added Value



*Kevin Hall*

Executive Director  
Chronic Pain Toronto  
[chronicpaintoronto@gmail.com](mailto:chronicpaintoronto@gmail.com)  
[www.chronicpaintoronto.com](http://www.chronicpaintoronto.com)

This research will assist in establishing best practice standards helping the industry as a whole. LPs can leverage this study to lobby the government for changes to enable greater access to market (i.e. retail outlets).

The study will also investigate preferred method of receiving medication and if the current mail order system is in the patients best interests.

As the medical cannabis industry is relatively new in Canada there is currently no independent third party analysis available at this time recommending best practices. Developing a consistent way to assess LPs will help develop industry standards in this emerging market.

Patients participating in study will sign a release of information, provide a picture of their prescription bottle with their name on it for authenticity purposes and will be asked to attest that the person taking the survey is a patient using an LP. They will receive a questionnaire by email and will be asked to complete and return the survey to Chronic Pain Toronto for data collection.

Participant's privacy will be a top priority and all names of those involved and personal details will be kept strictly confidential. The survey will be run by Dr. Sana-Ara Ahmed MD, FRCPC and our Clinical Researcher, Nabila Afreen a University of Toronto alumnus and a full report will be provided to all participating LPs and stakeholders.

Licensed Producers who are members of the CMCIA can participate in this study at a discounted \$750 fee, non-member fees will be \$1,000.

LPs that chose not to participate will be listed in the study with a comment indicating "declined to participate."

**To register for participation please send an email to [chronicpaintoronto@gmail.com](mailto:chronicpaintoronto@gmail.com) and further details will be shared with you directly.**